抗VEGF药物治疗继发性黄斑水肿的效果观察

Effect Observation of Anti-VEGF Drugs for Secondary Macular Edema

目的玻璃体腔内注射抗VEGF药物(阿柏西普)治疗视网膜静脉阻塞(RVO)继发黄斑水肿(ME)的效果观察.方法选取2019年6月—2020年2月于沈阳市第四人民医院眼科确诊的RVO继发黄斑水肿并接受玻璃体腔注射阿柏西普治疗患者共37例(38眼)作为研究对象,随访6个月,观察治疗前后最佳矫正视力(BCVA)、黄斑中心凹厚度(CMT)的变化.结果治疗后2周、1个月、2个月、3个月、6个月最佳矫正视力与治疗前相比,视力提高,差异均具有统计学意义(P<0.05);治疗后2周、1个月、2个月、3个月、6个月黄斑中心厚度与治疗前相比,厚度降低,差异均具有统计学意义(P<0.05).结论玻璃体腔内注射阿柏西普是一种治疗视网膜静脉阻塞继发黄斑水肿的安全、有效的方法.

Objective Effect observation of intravitreal injection of anti-VEGF drug(aflibercept)in the treatment of macular edema secondary to retinal vein occlusion.Methods A total of 37 patients(38 eyes)with macular edema(ME)secondary to retinal vein occlusion(RVO)who were diagnosed in our hospital from June 2019 to February 2020 and received intravitreal injection of aflibercept were retrospectively analyzed.They were followed up for 6 months to observe the changes of best corrected visual acuity(BCVA)and central macular thickness(CMT)before and after treatment.Results After 2 weeks,1 month,2 months,3 months,and 6 months treatment,the best corrected visual acuity was significantly improved compared with that before treatment(P<0.05).Moreover,after 2 weeks,1 month,2 months,3 months,and 6 months treatment,the central macular thickness was significantly lower than that before treatment(P<0.05).Conclusion Intravitreal injection of aflibercept is a safe and effective method for the treatment of macular edema secondary to retinal vein occlusion.